News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
860,429 Results
Type
Article (87407)
Company Profile (759)
Press Release (772237)
Multimedia
Podcasts (171)
Webinars (27)
Section
Business (233045)
Career Advice (4139)
Deals (39792)
Drug Delivery (134)
Drug Development (91245)
Employer Resources (202)
FDA (18277)
Job Trends (17397)
News (397368)
Policy (39924)
Tag
Academia (3005)
Academic (2)
Accelerated approval (18)
Adcomms (35)
Allergies (124)
Alliances (56979)
ALS (145)
Alzheimer's disease (1680)
Antibody-drug conjugate (ADC) (230)
Approvals (18291)
Artificial intelligence (484)
Autoimmune disease (69)
Automation (25)
Bankruptcy (406)
Best Places to Work (12633)
BIOSECURE Act (23)
Biosimilars (158)
Biotechnology (484)
Bladder cancer (124)
Brain cancer (52)
Breast cancer (481)
Cancer (3836)
Cardiovascular disease (337)
Career advice (3556)
Career pathing (38)
CAR-T (244)
CDC (57)
Cell therapy (677)
Cervical cancer (32)
Clinical research (75334)
Collaboration (1369)
Company closure (4)
Compensation (930)
Complete response letters (59)
COVID-19 (2952)
CRISPR (81)
C-suite (578)
Cystic fibrosis (133)
Data (4303)
Decentralized trials (2)
Denatured (60)
Depression (109)
Diabetes (449)
Diagnostics (7087)
Digital health (36)
Diversity (11)
Diversity, equity & inclusion (49)
Drug discovery (229)
Drug pricing (188)
Drug shortages (36)
Duchenne muscular dystrophy (202)
Earnings (98757)
Editorial (54)
Employer branding (25)
Employer resources (171)
Events (132868)
Executive appointments (984)
FDA (20699)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (6)
Frontotemporal dementia (14)
Funding (1242)
Gene editing (173)
Generative AI (48)
Gene therapy (545)
GLP-1 (1015)
Government (5380)
Grass and pollen (7)
Guidances (337)
Healthcare (20937)
HIV (48)
Huntington's disease (37)
IgA nephropathy (55)
Immunology and inflammation (239)
Immuno-oncology (20)
Indications (52)
Infectious disease (3185)
Inflammatory bowel disease (185)
Inflation Reduction Act (15)
Influenza (93)
Intellectual property (185)
Interviews (815)
IPO (17926)
IRA (59)
Job creations (5197)
Job search strategy (2865)
Kidney cancer (15)
Labor market (75)
Layoffs (639)
Leadership (33)
Legal (10148)
Liver cancer (91)
Longevity (12)
Lung cancer (546)
Lymphoma (261)
Machine learning (29)
Management (66)
Manufacturing (632)
MASH (137)
Medical device (14863)
Medtech (14886)
Mergers & acquisitions (22736)
Metabolic disorders (1144)
Multiple sclerosis (137)
NASH (23)
Neurodegenerative disease (227)
Neuropsychiatric disorders (60)
Neuroscience (2705)
NextGen: Class of 2025 (7687)
Non-profit (5095)
Now hiring (57)
Obesity (555)
Opinion (311)
Ovarian cancer (127)
Pain (162)
Pancreatic cancer (168)
Parkinson's disease (239)
Partnered (30)
Patents (413)
Patient recruitment (303)
Peanut (57)
People (66234)
Pharmaceutical (144)
Pharmacy benefit managers (27)
Phase I (23232)
Phase II (32709)
Phase III (24607)
Pipeline (2672)
Policy (295)
Postmarket research (3554)
Preclinical (10486)
Press Release (72)
Prostate cancer (195)
Psychedelics (51)
Radiopharmaceuticals (282)
Rare diseases (662)
Real estate (7421)
Recruiting (78)
Regulatory (27961)
Reports (64)
Research institute (2688)
Resumes & cover letters (651)
Rett syndrome (15)
RNA editing (15)
RSV (70)
Schizophrenia (134)
Series A (206)
Series B (154)
Service/supplier (30)
Sickle cell disease (79)
Special edition (25)
Spinal muscular atrophy (170)
Sponsored (40)
Startups (4318)
State (2)
Stomach cancer (17)
Supply chain (99)
Tariffs (95)
The Weekly (109)
Vaccines (1038)
Venture capital (66)
Weight loss (393)
Women's health (58)
Worklife (21)
Date
Today (143)
Last 7 days (538)
Last 30 days (2491)
Last 365 days (33590)
2025 (25965)
2024 (38142)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1279)
Alabama (80)
Alaska (7)
Arizona (302)
Arkansas (14)
Asia (50929)
Australia (8952)
California (9351)
Canada (2834)
China (881)
Colorado (400)
Connecticut (419)
Delaware (261)
Europe (117032)
Florida (1374)
Georgia (313)
Hawaii (3)
Idaho (67)
Illinois (806)
India (50)
Indiana (455)
Iowa (19)
Japan (313)
Kansas (124)
Kentucky (38)
Louisiana (20)
Maine (77)
Maryland (1268)
Massachusetts (7044)
Michigan (310)
Minnesota (559)
Mississippi (4)
Missouri (118)
Montana (33)
Nebraska (26)
Nevada (106)
New Hampshire (77)
New Jersey (2587)
New Mexico (32)
New York (2548)
North Carolina (1405)
North Dakota (10)
Northern California (4212)
Ohio (294)
Oklahoma (22)
Oregon (50)
Pennsylvania (1952)
Puerto Rico (19)
Rhode Island (46)
South America (1655)
South Carolina (48)
South Dakota (1)
Southern California (3574)
Tennessee (149)
Texas (1467)
United States (34616)
Utah (279)
Virginia (246)
Washington D.C. (83)
Washington State (808)
West Virginia (4)
Wisconsin (96)
Wyoming (1)
There are 860,429 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Personalized Cancer Vaccine Market Size to Exceed USD 8,501.14 Million by 2034
October 15, 2025
·
1 min read
GLP-1
Lilly’s Oral GLP-1 Bests Another Big Pharma Bestseller in Phase III Diabetes Trial
After beating Novo Nordisk’s semaglutide last month, Lilly’s much anticipated oral candidate orforglipron has taken down AstraZeneca’s Farxiga in a head-to-head trial.
October 15, 2025
·
2 min read
·
Annalee Armstrong
Gene therapy
Sarepta’s Not Done With Gene Therapy Yet as LGMD Asset Yields Promising Data
Despite announcing a broad pivot to siRNA earlier this year, Sarepta is following through with an investigational gene therapy: its limb-girdle muscular dystrophy candidate. But the treatment’s path forward, analysts say, is highly uncertain.
October 15, 2025
·
6 min read
·
Tristan Manalac
Funding
Pelage Pharmaceuticals Raises $120 Million To Grow Hair Loss Program
The company is pursuing a Phase III trial for its topical stem cell-rejuvenating molecule that aims to reactivate hair growth.
October 15, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
PolyActiva to Present Advancements in Next-Generation Ocular Micro-Implant Technology at Eyecelerator® @ AAO 2025
October 15, 2025
·
3 min read
Collaboration
Boehringer Ingelheim Bets up to Nearly $1B in ADC Play With AimedBio Deal
2025 has been a busy year for Boehringer Ingelheim, which has so far inked at least five hefty partnerships—including its latest one with South Korea’s AimedBio for an antibody-drug conjugate therapy for cancer.
October 15, 2025
·
2 min read
·
Tristan Manalac
ALS
BMS Deepens ALS Alliance With Insitro, Puts $2B+ On the Line
Bristol Myers Squibb and insitro first partnered in 2020 to develop induced pluripotent stem cell models of amyotrophic lateral sclerosis and frontotemporal dementia. Last December, BMS exercised its option for an ALS target.
October 15, 2025
·
1 min read
·
Tristan Manalac
Mergers & acquisitions
BioCryst Snaps Up Fellow Angiodema Player Astria for $700M
The acquisition will give BioCryst an investigational injectable drug for hereditary angioedema, potentially complementing its FDA-approved oral drug Orladeyo.
October 15, 2025
·
2 min read
·
Tristan Manalac
Gene therapy
FDA’s Second Platform Designation Goes to Krystal After Sarepta Withdrawal
After the FDA revoked Sarepta Therapeutics’ platform designation in July, Krystal Biotech is “poised to be the first major beneficiary” of this program, according to analysts at William Blair.
October 15, 2025
·
2 min read
·
Tristan Manalac
Press Releases
EyePoint Announces Pricing of Public Offering
October 15, 2025
·
8 min read
1 of 86,043
Next
